Anti‑inflammatory effect of polydeoxyribonucleotide on zoledronic acid‑pretreated and lipopolysaccharide‑stimulated RAW 264.7 cells

Han,Jin‑Hee; Jung,Junho; Hwang,Lakkyong; Ko,Il‑Gyu; Nam,Ok  Hyung; Kim,Mi  Sun; Lee,Jung‑Woo; Choi,Byung‑Joon; Lee,Deok‑Won

doi:10.3892/etm.2018.6186

Anti‑inflammatory effect of polydeoxyribonucleotide on zoledronic acid‑pretreated and lipopolysaccharide‑stimulated RAW 264.7 cells

Authors:
- Jin‑Hee Han
- Junho Jung
- Lakkyong Hwang
- Il‑Gyu Ko
- Ok Hyung Nam
- Mi Sun Kim
- Jung‑Woo Lee
- Byung‑Joon Choi
- Deok‑Won Lee
View Affiliations

Affiliations: Department of Anesthesiology and Pain Medicine, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea, Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyung Hee University, Seoul 02447, Republic of Korea, Department of Physiology, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea, Department of Pediatric Dentistry, School of Dentistry, Kyung Hee University, Seoul 02447, Republic of Korea
Published online on: May 18, 2018 https://doi.org/10.3892/etm.2018.6186
Pages: 400-405

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bisphosphonates are generally used as therapeutic agents for bone diseases. However, previous reports on bisphosphonates‑related osteonecrosis of the jaw (BRONJ) demonstrated that inflammation triggers and worsens the disease. Recently, polydeoxynucleotide (PDRN), an A2A receptor agonist, has been suggested for the treatment of various diseases and broadly studied for its anti‑inflammatory effect. The present study aimed to measure the effect of PDRN on macrophage cells treated with zoledronic acid (ZA) and lipopolysaccharide (LPS). Macrophage cells were cultured with ZA for 24 h, following which they were stimulated with LPS in the presence or absence of varying concentrations of PDRN for 24 h. The cell viability and nitric oxide (NO) production of the cells were analyzed. In addition, protein expression levels were quantified by western blotting. Cell viability was compromised and NO was overexpressed by ZA and LPS stimulation. However, under ZA and LPS stimulation cell viability was enhanced, and NO production, and inducible nitric oxide synthase, interleukin (IL)‑1β, ‑6, and tumor necrosis factor‑α overexpression were suppressed on exposure to PDRN. A2A receptor and vascular endothelial growth factor (VEGF) expression levels increased following PDRN treatment. These results indicate that PDRN treatment of macrophages inhibits the inflammatory cytokines induced by ZA and LPS stimulation. It was hypothesized that the inflammatory cytokines were inhibited through A2A activation by PDRN. In addition, increased VEGF expression may contribute to increased vascularization and subsequently improve the pathological condition in BRONJ. As inflammation and LPS may stimulate the occurrence of BRONJ, the present study postulated that PDRN is possibly a candidate for the therapeutic management of BRONJ by decreasing inflammation and increasing vascularization.

View Figures

View References

1	Pennanen N, Lapinjoki S, Urtti A and Mönkkönen J: Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res. 12:916–922. 1995. View Article : Google Scholar : PubMed/NCBI
2	Berenson JR and Lipton A: Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med. 50:237–248. 1999. View Article : Google Scholar : PubMed/NCBI
3	Lipton A: Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone. Cancer Treat Rev. 34 Suppl 1:S25–S30. 2008. View Article : Google Scholar : PubMed/NCBI
4	van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Löwik CW and Papapoulos SE: Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone. 33:805–811. 2003. View Article : Google Scholar : PubMed/NCBI
5	Pataki A, Muller K, Green JR, Ma YF, Li QN and Jee WS: Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: A comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec. 249:458–468. 1997. View Article : Google Scholar : PubMed/NCBI
6	Rogers MJ: New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 9:2643–2658. 2003. View Article : Google Scholar : PubMed/NCBI
7	Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 61:1115–1117. 2003. View Article : Google Scholar : PubMed/NCBI
8	Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B and O'Ryan F: American Association of Oral and Maxillofacial Surgeons: American Association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg. 72:1938–1956. 2014. View Article : Google Scholar : PubMed/NCBI
9	Spinelli G, Torresetti M, Lazzeri D, Zhang YX, Arcuri F, Agostini T and Grassetti L: Microsurgical reconstruction after bisphosphonate-related osteonecrosis of the jaw: Our experience with fibula free flap. J Craniofac Surg. 25:788–792. 2014. View Article : Google Scholar : PubMed/NCBI
10	Tsurushima H, Kokuryo S, Sakaguchi O, Tanaka J and Tominaga K: Bacterial promotion of bisphosphonate-induced osteonecrosis in Wistar rats. Int J Oral Maxillofac Surg. 42:1481–1487. 2013. View Article : Google Scholar : PubMed/NCBI
11	Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, et al: Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 23:826–836. 2008. View Article : Google Scholar : PubMed/NCBI
12	Xie C, Kang J, Li Z, Schauss AG, Badger TM, Nagarajan S, Wu T and Wu X: The açaí flavonoid velutin is a potent anti-inflammatory agent: Blockade of LPS-mediated TNF-α and IL-6 production through inhibiting NF-κB activation and MAPK pathway. J Nutr Biochem. 23:1184–1191. 2012. View Article : Google Scholar : PubMed/NCBI
13	Nicholas C, Batra S, Vargo MA, Voss OH, Gavrilin MA, Wewers MD, Guttridge DC, Grotewold E and Doseff AI: Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylation. J Immunol. 179:7121–7127. 2007. View Article : Google Scholar : PubMed/NCBI
14	Taira J, Nanbu H and Ueda K: Nitric oxide-scavenging compounds in Agrimonia pilosa Ledeb on LPS-induced RAW264.7 macrophages. Food Chem. 115:1221–1227. 2009. View Article : Google Scholar
15	Muratsu D, Yoshiga D, Taketomi T, Onimura T, Seki Y, Matsumoto A and Nakamura S: Zoledronic acid enhances lipopolysaccharide-stimulated proinflammatory reactions through controlled expression of SOCS1 in macrophages. PLoS One. 8:e679062013. View Article : Google Scholar : PubMed/NCBI
16	Altavilla D, Bitto A, Polito F, Marini H, Minutoli L, Di Stefano V, Irrera N, Cattarini G and Squadrito F: Polydeoxyribonucleotide (PDRN): A safe approach to induce therapeutic angiogenesis in peripheral artery occlusive disease and in diabetic foot ulcers. Cardiovasc Hematol Agents Med Chem. 7:313–321. 2009. View Article : Google Scholar : PubMed/NCBI
17	Squadrito F, Bitto A, Altavilla D, Arcoraci V, De Caridi G, De Feo ME, Corrao S, Pallio G, Sterrantino C, Minutoli L, et al: The effect of PDRN, an adenosine receptor A2A agonist, on the healing of chronic diabetic foot ulcers: Results of a clinical trial. J Clin Endocrinol Metab. 99:E746–E753. 2014. View Article : Google Scholar : PubMed/NCBI
18	Gomez G and Sitkovsky MV: Targeting G protein-coupled A2a adenosine receptors to engineer inflammation in vivo. Int J Biochem Cell Biol. 35:410–414. 2003. View Article : Google Scholar : PubMed/NCBI
19	Cronstein BN: Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol (1985). 76:5–13. 1994. View Article : Google Scholar : PubMed/NCBI
20	Bitto A, Polito F, Irrera N, D'Ascola A, Avenoso A, Nastasi G, Campo GM, Micali A, Bagnato G, Minutoli L, et al: Polydeoxyribonucleotide reduces cytokine production and the severity of collagen-induced arthritis by stimulation of adenosine A(2A) receptor. Arthritis Rheum. 63:3364–3371. 2011. View Article : Google Scholar : PubMed/NCBI
21	Jeong EK, Jang HJ, Kim SS, Lee SY, Oh MY, Kim HJ, Eom DW, Ham JY and Han DJ: Protective effect of polydeoxyribonucleotide against renal ischemia-reperfusion injury in mice. Transplant Proc. 48:1251–1257. 2016. View Article : Google Scholar : PubMed/NCBI
22	Ramanathan M, Pinhal-Enfield G, Hao I and Leibovich SJ: Synergistic up-regulation of vascular endothelial growth factor (VEGF) expression in macrophages by adenosine A2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter. Mol Biol Cell. 18:14–23. 2007. View Article : Google Scholar : PubMed/NCBI
23	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI
24	Ziebart T, Pabst A, Klein MO, Kämmerer P, Gauss L, Brüllmann D, Al-Nawas B and Walter C: Bisphosphonates: Restrictions for vasculogenesis and angiogenesis: Inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig. 15:105–111. 2011. View Article : Google Scholar : PubMed/NCBI
25	Naik NH and Russo TA: Bisphosphonate-related osteonecrosis of the jaw: The role of actinomyces. Clin Infect Dis. 49:1729–1732. 2009. View Article : Google Scholar : PubMed/NCBI
26	Ikeda T, Kuraguchi J, Kogashiwa Y, Yokoi H, Satomi T and Kohno N: Successful treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ) patients with sitafloxacin: New strategies for the treatment of BRONJ. Bone. 73:217–222. 2015. View Article : Google Scholar : PubMed/NCBI
27	Boff RC, Salum FG, Figueiredo MA and Cherubini K: Important aspects regarding the role of microorganisms in bisphosphonate-related osteonecrosis of the jaws. Arch Oral Biol. 59:790–799. 2014. View Article : Google Scholar : PubMed/NCBI
28	Sakaguchi O, Kokuryo S, Tsurushima H, Tanaka J, Habu M, Uehara M, Nishihara T and Tominaga K: Lipopolysaccharide aggravates bisphosphonate-induced osteonecrosis in rats. Int J Oral Maxillofac Surg. 44:528–534. 2015. View Article : Google Scholar : PubMed/NCBI
29	Burney S, Caulfield JL, Niles JC, Wishnok JS and Tannenbaum SR: The chemistry of DNA damage from nitric oxide and peroxynitrite. Mutat Res. 424:37–49. 1999. View Article : Google Scholar : PubMed/NCBI
30	Makkonen N, Hirvonen MR, Teräväinen T, Savolainen K and Mönkkönen J: Different effects of three bisphosphonates on nitric oxide production by RAW 264 macrophage-like cells in vitro. J Pharmacol Exp Ther. 277:1097–1102. 1996.PubMed/NCBI
31	Kobayashi Y: The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation. J Leukoc Biol. 88:1157–1162. 2010. View Article : Google Scholar : PubMed/NCBI
32	Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G and Lo Cascio V: The acute-phase response after bisphosphonate administration. Calcif Tissue Int. 41:326–331. 1987. View Article : Google Scholar : PubMed/NCBI
33	Koide N, Odkhuu E, Naiki Y, Tsolmongyn B, Ito K, Komatsu T, Yoshida T and Yokochi T: Augmentation of LPS-induced vascular endothelial cell growth factor production in macrophages by transforming growth factor-β1. Innate Immun. 20:816–825. 2014. View Article : Google Scholar : PubMed/NCBI
34	Ben-Av P, Crofford LJ, Wilder RL and Hla T: Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis. FEBS Lett. 372:83–87. 1995. View Article : Google Scholar : PubMed/NCBI
35	De Ponti C, Carini R, Alchera E, Nitti MP, Locati M, Albano E, Cairo G and Tacchini L: Adenosine A2a receptor-mediated, normoxic induction of HIF-1 through PKC and PI-3K-dependent pathways in macrophages. J Leukoc Biol. 82:392–402. 2007. View Article : Google Scholar : PubMed/NCBI
36	Polito F, Bitto A, Galeano M, Irrera N, Marini H, Calò M, Squadrito F and Altavilla D: Polydeoxyribonucleotide restores blood flow in an experimental model of ischemic skin flaps. J Vasc Surg. 55:479–488. 2012. View Article : Google Scholar : PubMed/NCBI